Apr 2026 (Q3 FY26) — Jun 11, 2026
Zedge Q3 FY26 — GAAP-profitable quarter on record per-user monetization and 32% subscription growth
Read the full callZedge earnings: last reported Thu, 11 Jun 2026, for the quarter ended Apr 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 8.0 | +3.0% YoY | Quarterly, as filed | Quarter to Apr 2026 | Revenue from operations as filed. |
| Operating margin | 13.4 | +11.4 pts YoY | Operating profit / revenue | Quarter to Apr 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.93 | +400.5% YoY | Quarterly, as filed | Quarter to Apr 2026 | Profit after tax as filed. |
Price
1Y: $3.1 on 17 Oct 2025 → $2.79. High $4.16 (12 Jun 2026), low $2.27 (2 Dec 2025).
Overview
Call summaries
Zedge Q3 FY26 — GAAP-profitable quarter on record per-user monetization and 32% subscription growth
Read the full callEvery analysed call
Financials
Net profit, year on year: +401% (quarter to apr 2026 against apr 2025).
| Line item | Jul 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 7 | 7 | 8 | 7 | 8 | 8 | 8 |
| Operating profit | -0 | -0 | -2 | 0 | -1 | 1 | -3 | 1 |
| Operating margin | −0.8% | −6.3% | −31.8% | 2.1% | −9.6% | 12.0% | −35.0% | 13.4% |
| Profit before tax | 0 | -0 | -2 | 0 | -1 | 1 | -3 | 1 |
| Tax rate | 124.2% | −16.9% | 21.3% | 32.2% | 1.2% | 22.8% | 21.2% | 21.7% |
| Net profit | -0 | -0 | -2 | 0 | -1 | 1 | -2 | 1 |
| EPS ($ per share) | — | -0.02 | -0.12 | 0.01 | — | 0.06 | -0.18 | 0.07 |
| Line item | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | — | — | — |
| Reserves | -12 | -15 | -16 | -8 | 2 | -4 | -13 | -16 |
| Total liabilities | 2 | 2 | 3 | 4 | 10 | 8 | 7 | 10 |
| Fixed assets | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 |
| Total assets | 12 | 9 | 12 | 37 | 55 | 47 | 38 | 36 |
| Line item | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | 0 | 2 | 10 | 11 | 3 | 6 | 3 |
| Cash from investing | -2 | -2 | -1 | -5 | -19 | -2 | -1 | -1 |
| Cash from financing | 0 | -0 | 2 | 15 | -0 | 0 | -3 | -4 |
| Net cash flow | — | -2 | 4 | 20 | -8 | 1 | 2 | -1 |
| Capital expenditure | — | — | — | — | -0 | -0 | -0 | -0 |
| Free cash flow | — | — | — | — | 11 | 3 | 6 | 3 |
15 filings between Jan 5, 2026 and Sep 25, 2026.
Purchases
$0
2 purchases by 2 insiders
Sales
None
No insider sold shares.
Some filings report no price, so the dollar figures above are a floor, not a total.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| JONAS HOWARD S | $0 | — | Sep 25, 2026 |
| GIBBER ELLIOT | $0 | — | Sep 11, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | JONAS HOWARD S Director | Purchase | 2,218,430 | — |
| Sep 25, 2026 | REICH JONATHAN CEO & President | Tax withheld | 50,471 | $152.4K |
| Sep 25, 2026 | REICH JONATHAN CEO & President | Option exercise | 60,000 | $136.2K |
| Sep 11, 2026 | GIBBER ELLIOT Director | Purchase | 221,843 | — |
| Sep 8, 2026 | JONAS MICHAEL C Executive Chairman | Option exercise | 4,233 | — |
| Sep 7, 2026 | REICH JONATHAN CEO & President | Option exercise | 6,467 | — |
| Sep 7, 2026 | Tsai Yi CFO & Treasurer | Tax withheld | 827 | $2.5K |
| Sep 7, 2026 | Tsai Yi CFO & Treasurer | Option exercise | 2,000 | — |
| Sep 7, 2026 | REICH JONATHAN CEO & President | Tax withheld | 2,331 | $6.9K |
| May 29, 2026 | REICH JONATHAN CEO & President | Option exercise | 181,616 | $314.2K |
| May 29, 2026 | REICH JONATHAN CEO & President | Tax withheld | 132,226 | $398.0K |
| Jan 5, 2026 | GHERMEZIAN MARK Director | Award | 12,027 | $35.0K |
| Jan 5, 2026 | PACKER PAUL Director | Award | 12,027 | $35.0K |
| Jan 5, 2026 | SUESS GREGORY Director | Award | 12,027 | $35.0K |
| Jan 5, 2026 | GIBBER ELLIOT Director | Award | 12,027 | $35.0K |
| Sep 8, 2025 | Tsai Yi CFO & Treasurer | Option exercise | 2,000 | — |
| Sep 8, 2025 | Tsai Yi CFO & Treasurer | Tax withheld | 827 | $2.5K |
| Sep 8, 2025 | REICH JONATHAN CEO & President | Option exercise | 6,466 | — |
| Sep 8, 2025 | REICH JONATHAN CEO & President | Tax withheld | 2,331 | $7.2K |
| Sep 8, 2025 | JONAS MICHAEL C Executive Chairman | Option exercise | 4,233 | — |
| Jun 25, 2025 | GHERMEZIAN MARK Director | Sale | 25,767 | $102.9K |
| Jun 24, 2025 | GHERMEZIAN MARK Director | Sale | 46,683 | $189.8K |
| Apr 16, 2025 | GIBBER ELLIOT Director | Purchase | 1,999 | $4.4K |
| Apr 15, 2025 | GIBBER ELLIOT Director | Purchase | 5,000 | $10.2K |
| Apr 11, 2025 | GIBBER ELLIOT Director | Purchase | 5,000 | $9.7K |
| Mar 21, 2025 | SUESS GREGORY Director | Purchase | 2,175 | $5.0K |
| Mar 20, 2025 | SUESS GREGORY Director | Purchase | 2,275 | $5.1K |
| Mar 19, 2025 | SUESS GREGORY Director | Purchase | 2,175 | $4.9K |
| Mar 18, 2025 | SUESS GREGORY Director | Purchase | 2,200 | $5.0K |
| Jan 6, 2025 | GIBBER ELLIOT Director | Award | 13,208 | $35.0K |
| Jan 6, 2025 | SUESS GREGORY Director | Award | 13,208 | $35.0K |
| Jan 6, 2025 | GHERMEZIAN MARK Director | Award | 13,208 | $35.0K |
| Jan 6, 2025 | PACKER PAUL Director | Award | 13,208 | $35.0K |
| Sep 7, 2024 | Tsai Yi CFO & Treasurer | Tax withheld | 1,250 | $3.9K |
| Sep 7, 2024 | Tsai Yi CFO & Treasurer | Option exercise | 3,024 | — |
| Sep 7, 2024 | REICH JONATHAN CEO & President | Tax withheld | 2,635 | $8.3K |
| Sep 7, 2024 | REICH JONATHAN CEO & President | Option exercise | 7,308 | — |
| Sep 7, 2024 | JONAS MICHAEL C Executive Chairman | Option exercise | 3,654 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Zedge, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading